Results 231 to 240 of about 517,111 (322)
The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series. [PDF]
Ch'en PY +3 more
europepmc +1 more source
This study identifies platelet‐derived extracellular vesicles as key immunometabolic regulators in COVID‐19. The delivery of tRF‐His‐GTG‐1 to neutrophils activates TLR8mTOR signaling, disrupts lipophagy, and amplifies NET‐mediated inflammation. Importantly, targeting this axis restores neutrophil homeostasis, offering a potential therapeutic strategy ...
Tsai‐Ling Liao +5 more
wiley +1 more source
Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling. [PDF]
Knight B +26 more
europepmc +1 more source
Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma. [PDF]
Li W, An N, Wang M, Liu X, Mei Z.
europepmc +1 more source
The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
Alexander Egeberg +4 more
openalex +1 more source
The preferred derivative JX3212 demonstrates strong inhibitory activity against Kir4.1 with favorable druggability and shows significant antidepressant efficacy in vivo. Abstract Major depressive disorder is a serious psychiatric disorder for which novel and fast‐acting antidepressants are required.
Sisi Wang +15 more
wiley +1 more source
Combination of mechanical debridement and interleukin 12 or interleukin 23 therapy for refractory facial pyoderma gangrenosum with NOD2 mutation. [PDF]
Vague M +4 more
europepmc +1 more source
Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. [PDF]
Sewell GW, Kaser A.
europepmc +1 more source

